Nasdaq-listed Jazz Pharmaceuticals, a global biopharma company, has through its wholly-owned subsidiary Jazz Investments I Limited, issued US$850m of 3.125% exchangeable senior 144a notes due 2030. A US$150m overallotment allowance…
Ireland: Jazz pays down debt with proceeds from 144a exchangeable notes issue
…
…






